secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2024-08-20T23:59:59+00:00
Accession:  0001104659-24-091315
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents amends royalty agreement with ROKK, redefines gross revenue scope
------------------------------------------------------------------------------

- Royalty rate remains 3% of gross revenues from CytoSorb sales under amended agreement.
- Amended and Restated Agreement clarifies definitions of 'gross revenue' with specified deductions.
- Covered Products now explicitly include CytoSorb, VetResQ, ECOS-300CY, and certain DrugSorb versions.
- Agreement dated August 16, 2024, amends the original 2003 Letter Agreement with ROKK.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924091315/0001104659-24-091315-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465924091315/tm2422183-1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-091315

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer